Qualigen Therapeutics is a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation. Our investigational QN-302 compound is a small molecule selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells; such binding could, by stabilizing the G4s against “unwinding,” help inhibit cancer cell proliferation. The investigational compounds within Qualigen’s family of Pan-RAS oncogene protein-protein interaction inhibitor small molecules are believed to inhibit or block the binding of mutated RAS genes’ proteins to their effector proteins, thereby leaving the proteins from the mutated RAS unable to cause further harm. In theory, such mechanism of action may be effective in the treatment of about one quarter of all cancers, including certain forms of pancreatic, colorectal, and lung cancers. Our investigational QN-247 compound inhibits nucleolin, a key multi-functional regulatory protein that is overexpressed in cancer cells; QN-247 may thereby be able to inhibit the cells’ proliferation. QN-247 has shown promise in preclinical studies for the treatment of acute myeloid leukemia (AML).
In July 2023, Qualigen sold its FastPack® diagnostics business to Chembio Diagnostics, Inc., an American subsidiary of French diagnostics provider BIOSYNEX Group, a leader in the design and distribution of rapid tests.
Healthcare
Pharmaceutical Preparations (2834)
Pharmaceutical Preparation Manufacturing (325412)
Biotechnology
2042 Corte del Nogal
Suite B
Carlsbad, CA 92011
December 31st
EQ Shareowner Services
PO Box 64874
St Paul MN 55164
T: 800-468-9716
ShareownerOnline.com
Baker Tilly US, LLP
Reed Smith LLP
Qualigen Therapeutics, Inc.
2042 Corte del Nogal
Suite B
Carlsbad, CA 92011
T: +760-918-9165
F: 760-918-9127
ir@qualigentx.com
EQ Shareowner Services
PO Box 64874
St Paul, MN 55164
T: +8004689716
ShareownerOnline.com
©2023 QUALIGEN THERAPEUTICS, INC. (NASDAQ: QLGN) | PRIVACY POLICY | TERMS OF SERVICE
CONTACT US | LET’S CONNECT: